info icon

This is a non-core endpoint: only basic statistics are computed.

See its core counterpart C3_EYE_ADNEXA_EXALLC for full statistics.

Malignant neoplasm of eye and adnexa

C3_EYE_ADNEXA

No definition available.

Endpoint definition

FinnGen phenotype data

392423 individuals

diagram downward connector

Apply sex-specific rule None

392423

diagram downward connector

Check conditions None

392423

diagram downward connector
diagram bullet

Check pre-conditions, main-only, mode, registry filters

Cause of death: ICD-10 C69
Cause of death: ICD-9 190
Cause of death: ICD-8 190
Cancer registry: Topography ICD-O-3 C69
Cancer registry: Morphology ICD-O-3 ANY
Cancer registry: Behaviour codes 3

2 out of 7 registries used, show all original rules.

209

diagram downward connector

Check minimum number of events None

209

diagram downward connector

Include endpoints None

209

diagram downward connector
diagram bullet diagram downward connector

Remove individuals based on genotype QC

206

diagram downward connector
C3_EYE_ADNEXA

Control definitions

Controls for this endpoint are individuals that are not cases.

Extra metadata

Level in the ICD hierarchy 4
First used in FinnGen datafreeze DF9

Similar endpoints

List of similar endpoints to Malignant neoplasm of eye and adnexa based on the number of shared cases.

Venn diagram with an highlighted set fully inside another set Broader endpoints:

Venn diagram with a set fully inside an highlighted set Narrower endpoints:

Show all endpoint correlations

Summary Statistics

Key figures

All Female Male
Number of individuals 206 93 113
Unadjusted prevalence (%) 0.05 0.04 0.07
Mean age at first event (years) 55.52 54.29 56.53

Mortality

Not a core endpoint, no data to show.

Age distribution of first events

Year distribution of first events

Cumulative Incidence

Not a core endpoint, no data to show.

Correlations

Index endpoint: C3_EYE_ADNEXA – Malignant neoplasm of eye and adnexa
GWS hits:

Survival analyses between endpoints

Not a core endpoint, no data to show.

Drugs most likely to be purchased after Malignant neoplasm of eye and adnexa

Endpoint not on priority list, no data to show.